Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial
Published inClinical cancer research, vol. 15, no. 17, p. 5528-5533
Publication date2009
Abstract
Keywords
- Antineoplastic Combined Chemotherapy Protocols
- Camptothecin/administration & dosage/analogs & derivatives
- Chemotherapy, Adjuvant
- Colonic Neoplasms/drug therapy/mortality
- Disease-Free Survival
- Fluorouracil/administration & dosage
- Glucuronosyltransferase/genetics/metabolism
- Humans
- Microsatellite Instability
- Oligonucleotide Array Sequence Analysis
- Polymorphism, Single Nucleotide/genetics
- Prospective Studies
- Proto-Oncogene Proteins/genetics/metabolism
- Proto-Oncogene Proteins B-raf/genetics/metabolism
- Smad4 Protein/metabolism
- Telomerase/metabolism
- Tumor Markers, Biological/genetics/metabolism
- Tumor Suppressor Protein p53/metabolism
- Ras Proteins/genetics/metabolism
Affiliation
Research group
Citation (ISO format)
BOSMAN, Fred T. et al. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. In: Clinical cancer research, 2009, vol. 15, n° 17, p. 5528–5533. doi: 10.1158/1078-0432.CCR-09-0741
Main files (1)
Article (Published version)
Identifiers
- PID : unige:5493
- DOI : 10.1158/1078-0432.CCR-09-0741
- PMID : 19690194
ISSN of the journal1078-0432